首页 | 本学科首页   官方微博 | 高级检索  
检索        

子宫颈癌HPV16/18感染与微血管密度和血管内皮生长因子表达的关系
引用本文:陈利友,姚济芬,石一复.子宫颈癌HPV16/18感染与微血管密度和血管内皮生长因子表达的关系[J].浙江医学,2006,28(7):519-522,525.
作者姓名:陈利友  姚济芬  石一复
作者单位:310006,杭州,浙江大学医学院附属妇产科医院
摘    要:目的 探讨人乳头状瘤病毒16/18(HPV16/18)在子宫颈癌组织中的感染情况及与微血管密度(MVD)和血管内皮生长因子(VEGF)表达的关系。方法 用原位杂交法检测HPV16/18在60例子宫颈癌(鳞癌40例、腺癌20例)、29例宫颈上皮内肿瘤(CIN)和16例正常子宫颈组织中的HPV16/18感染情况;采用免疫组织化学方法(SP)检测VEGF蛋白的表达,并以CD34抗原作为血管内皮细胞标记,测定其微血管密度。结果 HPV16/18在子宫颈鳞癌、腺癌、CIN和正常子宫颈组织中感染率分别为67.50%(27/40)、35.00%(7/20)、68.97%(20/29)、6.25%(1/16)。HPV16/18感染率鳞癌组与腺癌组和正常组比较差异均有显著性意义(均P〈0.01),而鳞癌组与CIN组相比差异无显著性意义(P〉0.05)。随着宫颈病变的进展,MVD逐渐增大,VEGF的阳性表达率渐增高。MVD在以上5种组织间相比差异均有极显著性意义(均P〈0.01)。VEGF在子宫颈鳞癌、腺癌、CIN、正常宫颈组织细胞质中的阳性表达率分别为95.00%(38/40)、100.00%(20/20)、82.80%(24/29)、18.80%(3/16)。病变患者与正常者相比差异有极显著性意义(P〈0.01)。HPV16/18感染与VEGF表达呈正相关(r=0.245,P〈0.05),而与MVD无相关性(r=.04,P〉0.05);VEGF的表达与MVD无相关性(r=0.01,P〉0.05)。淋巴转移阳性者MVD的表达量较阴性者高(P〈0.05)。结论 在子宫颈癌的发生发展中HPV16/18的感染起一定的作用,MVD与VEGF在子宫颈组织的不同病变中的表达均有差异性,推测VEGF有促进子宫颈癌组织血管形成作用,MVD与子宫颈癌的恶性程度密切相关。HPV16/18感染可能通过促进VEGF的表达而有利于子宫颈癌组织的生长。

关 键 词:人乳头状瘤病毒  微血管密度  血管内皮生长因子  血管形成  宫颈肿瘤  原位杂交  免疫组化
收稿时间:2005-10-20
修稿时间:2005-10-20

HPV Infection and its Correlation with Microvessel Density and Vascular Endothelial Growth Factor in Human Cervical Carcinoma
CHEN LiYou,YAO Jifen,SHI Yifu.HPV Infection and its Correlation with Microvessel Density and Vascular Endothelial Growth Factor in Human Cervical Carcinoma[J].Zhejiang Medical Journal,2006,28(7):519-522,525.
Authors:CHEN LiYou  YAO Jifen  SHI Yifu
Abstract:Objective To investigate infection of human papillomavirus 16/18(HPV16/18)and its correlation with microvessel density (MVD) and expression of vascular endothelial growth factor (VEGF) in human cervical carcinomas. Methods Tissue specimens were collected from 60 cases of cervical carcinoma (40 squamous cell carcinoma and 20 adenocarcinoma), 29 cases of cervical intraepithelial neoplasia (CIN) and 16 cases of normal cervices. HPV16/18 DNA was detected with in site hybridization method, VEGF and CD34 were stained immunohistochemically (SP) and density of microvessel was assayed. Results The infection rates of HPV16/18 in squamous cell carcinoma, adenocarcinoma, CIN and normal cervical epithelium were 67.5%, 35.0%, 69.0%, 6.3% respectively. There were significant differences when squamous cell carcinoma was compared with adenocarcinoma and the normal cervical epithelium (P<0.05), CIN was compared with adenocarcinoma and normal epithelium (P<0.05). There were statistically significant differences between adenocarcinoma and the normal epithelium (P<0.05), and between glandular and squamous cell carcinoma and normal group (P<0.01), but no significant difference between CIN and adenocarcinoma. The MVD and expression rate of VEGF were gradually increased with the progress cervical lesions. There were significant differences among the above 4 groups for MVD (P<0.01). The positive rates of VEGF in squamous-cell carcinoma and adenocarcinoma, CIN and in normal cervical epithelium were 95.0%?100.0%?82.8%?18.8% respectively. There were statistically significant differences between these cervical lesion groups and the control group. The infection of HPV16/18 and expression of VEGF was positively correlated (r=0.245,P<0.05) , but not correlated with MVD(r=0.01,P>0.05); and there was no correlation between expression of VEGF and MVD(r=0.04,P>0.05). There were significant differences in MVD between cases with positive pelvic node metastasis and those with negative pelvic node metastasis(P<0.05). No significant correlation was found between the infection of HPV16/18 and expression of VEGF and the tumor diameter, clinical stage, pathologic grade and pelvic node metastasis. Conclusions TThe infection of HPV16/18 may play a role in the progress of carcinoma of the uterine cervix .The expression of MVD and VEGF are significant correlation in different cervical lesions.
Keywords:HPV Microvessel density Vascular endothelial growth factor Angiogenesis Cervixneoplasm Immunohistochemistry In site hybridization
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号